Top Stocks To Watch For 2023


The National Football League (NFL) has barred its teams from selling sponsorships to cryptocurrency trading firms or NFTs, as it evaluates the cryptocurrency industry.  

According to the report, the league is developing an official strategy for crypto and NFTs and till then the suspensions remain in place. 

NFL’s 32 team members are prohibited from selling ads or sponsorships to crypto coins, crypto marketplaces, and other companies that sell blockchain assets, as well as releasing their own NFTs. 

The league now has a set of rules that significantly limit what teams can use cryptocurrency. 

According to leagues' new rules, teams can collaborate with crypto adjacent companies, but partnerships with those directly tied to crypto, such as exchanges, go against the new guidelines.

“The teams can get sponsorships from companies whose primary business is providing investment advisory and or fund management services in connection with cryptocurrency, provided that such advertising sponsorship rights are limited to promoting the company’s corporate brands,” the report says. 


NFL players are allowed to have crypto and blockchain company sponsorships. 

Tom Brady and top draft choice Trevor Lawrence both have deals with FTX. In addition, Brady launched his own NFT platform, Autograph, in August.

The NFL was the last major sports league in the USA to allow gambling and liquor sponsors.

Other leagues have moved further with digital assets. NBA Top Shot, created through a partnership between Dapper Labs and the NBA, has hosted $675 million in sales since its beta launch in May 2020. 

Also Read: 10 Most Valuable NFL Teams: How Media Rights And A Super Bowl Affected The 2021 List

Top Stocks To Watch For 2023: PharmaCyte Biotech, Inc.(PMCB)


PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer and diabetes in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable non-metastatic pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other tumors, including encapsulated genetically modified living cells. It is also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes; and therapies for cancer based on the constituents of the cannabis plant. The company has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is based in Laguna Hills, California.


Advisors’ Opinion:

  • [By Thomas Niel]

    Full-on approval for any possible treatments remains far away. But progress otherwise with the FDA continues, such as the company putting in its Investigational New Drug (IND) application, which it is slated to do this quarter. Is MNMD stock high-risk and richly-priced? Yes. But it may be worth it as the chances of eventual commercialization grow.

    PharmaCyte Biotech (PMCB)

  • [By ]

    PharmaCyte Biotech  (PMCB) – Get Report, which debuted on the Nasdaq last week, was skyrocketing as the chief executive laid out plans for the biotech company. 

Top Stocks To Watch For 2023: AcelRx Pharmaceuticals Inc.(ACRX)


AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain in the United States. The company develops ARX-01, a Sufentanil NanoTab PCA system, which completed Phase II clinical trial for acute post-operative pain. The Sufentanil NanoTab PCA system consists of sufentanil, a high therapeutic index opioid; NanoTabs, a non-invasive sublingual dosage form; and a handheld PCA device that enables simple patient-controlled delivery of NanoTabs in the hospital setting and eliminates the risk of programming errors. Its products also include ARX-02, a Sufentanil NanoTab BTP Management System that completed Phase II clinical trial for the treatment of cancer breakthrough pain; and ARX-03, a Sufentanil/Triazolam NanoTab, which completed Phase II clinical trial to provide mild sedation, anxiety reduction, and pain relief for patients undergoing painful procedures in a ph ysician?s office. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood, California.


Advisors’ Opinion:

  • [By Keith Speights]

    Shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) were sinking by 11.3% as of 10:47 a.m. EST on Friday. The specialty pharmaceutical company announced its fourth-quarter and full-year 2018 results after the market closed on Thursday.

  • [By Shane Hupp]

    TRADEMARK VIOLATION WARNING: “AcelRx Pharmaceuticals (ACRX) Releases Earnings Results, Beats Expectations By $0.05 EPS” was first published by Ticker Report and is the property of of Ticker Report. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at www.tickerreport.com/banking-finance/4206297/acelrx-pharmaceuticals-acrx-releases-earnings-results-beats-expectations-by-0-05-eps.html.

  • [By George Budwell, Chuck Saletta, and Todd Campbell]

    Armed with this insight, we asked three of our Motley Fool contributors which top small-cap stocks have their attention right now. They named AcelRx Pharmaceuticals (NASDAQ:ACRX), Realogy Holdings (NYSE:RLGY),  and Regenxbio Inc. (NASDAQ:RGNX). Read on to find out why. 

  • [By Keith Speights]

    Surprises for small biotechs are often of the unpleasant variety. But that wasn’t the case for AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) on Wednesday.

Top Stocks To Watch For 2023: Greenlight Capital Re Ltd.(GLRE)


Greenlight Capital Re, Ltd., through its subsidiaries, operates in the property and casualty reinsurance business in the United States, Europe, the Caribbean, and internationally. The company?s frequency business includes contracts containing smaller losses emanating from multiple events and enables the clients to increase their own underwriting capacity; and severity business consists of contracts with the potential for significant losses emanating from one event or multiple events. It offers personal and commercial property, general and marine liability, motor liability, motor physical damage, professional liability, financial, health, medical malpractice, and workers? compensation reinsurance products. Greenlight Capital Re, Ltd. sells its products primarily through reinsurance brokers. The company was founded in 2004 and is headquartered in Grand Cayman, the Cayman Islands.


Advisors’ Opinion:

  • [By ]

    For instance, Bill Ackman’s Pershing Square Holdings has lost money in the previous three years (he’s since turned that around and is doing quite well so far this year). And David Einhorn’s Greenlight Capital (Nasdaq: GLRE) has greatly underperformed over the last three years.

  • [By Logan Wallace]

    Greenlight Capital Re (NASDAQ:GLRE) was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.

Top Stocks To Watch For 2023: Oconee Federal Financial Corp.(OFED)


Oconee Federal Financial Corp. operates as a holding company for Oconee Federal Savings and Loan Association that provides various banking products and services in the Oconee County area of northwestern South Carolina and the northeast area of Georgia. The company’s deposit products include demand, NOW, money market, savings, certificates of deposit, and individual retirement accounts. Its loan portfolio comprises one-to-four family residential real estate loans; multi-family real estate loans; nonresidential real estate loans secured by real estate mortgages on churches, owner-occupied and non-owner occupied commercial buildings of various types, retail and office buildings, hotels, and other business and industrial properties; construction and land loans; home equity loans and lines of credit; agricultural loans; commercial and industrial loans; and consumer loans for the purchase of automobiles and boats, and for other legitimate personal purposes. Oconee Federal Financial Corp. operates through its executive office and seven branch offices. The company was founded in 1924 and is based in Seneca, South Carolina. Oconee Federal Financial Corp. is a subsidiary of Oconee Federal, MHC.

Leave a Reply

Your email address will not be published.